Drug Survival of Biologic Therapy for Moderate‐to‐Severe Psoriasis in a Latin American Specialized Psoriasis Center: A 7‐Year Experience
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/1864210 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 03.11.2026. Verfasst von Laura I. Vallejo-Londoño und 6 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad CES.
Abstract (Originalsprache)
Background
Drug survival integrates effectiveness, safety, and access in routine psoriasis care, yet real‐world Latin American data are scarce. We assessed drug survival and explanatory factors of discontinuation among bio‐naïve adults with moderate‐to‐severe psoriasis in Colombia.
Methods
We conducted a retrospective cohort study using secondary electronic health record data from a multidisciplinary clinic in Medellín, Colombia (CLIPSO) from January 2018 to December 2024. Eligible adults met at least one severity criterion (PASI ≥ 10, BSA ≥ 10, or DLQI ≥ 10), initiated a first biologic, and had ≥ 3 months of treatment. Drug survival was the time from initiation to discontinuation for any reason. Records with > 60% missing data underwent targeted chart review to verify key variables. Kaplan–Meier curves (log‐rank) and Cox proportional hazards models were used.
Results
The cohort included 1098 patients (48.8% women); 30.1% discontinued therapy. Therapeutic failure was the leading reason (58.2%), whereas adverse events were less frequently reported (11.2%). Drug survival declined to ∼50% at 60 months and ∼43% by 80 months. In multivariable analyses, adalimumab showed higher discontinuation risk (aHR = 1.36; 95% CI: 1.0001–1.84), whereas risankizumab (aHR = 0.41; 95% CI: 0.21–0.80), guselkumab (aHR = 0.42; 95% CI: 0.26–0.68), ixekizumab (aHR = 0.59; 95% CI: 0.41–0.85), and secukinumab (aHR = 0.67; 95% CI 0.47–0.97) showed better persistence. The presence of a high burden of comorbidities increased risk (aHR = 1.71; 95% CI: 1.12–2.63), whereas prior systemic therapy was protective (aHR = 0.45; 95% CI: 0.28–0.72).
Conclusions
Drug survival differed across biologics in this Colombian real‐world cohort, with interleukin‐23 and interleukin‐17 inhibitors demonstrating greater persistence in both bivariate and multivariable models and comorbidity burden identifying patients at higher risk of discontinuation.
Förderung
- Universidad CES
Zitieren
APA
Vallejo-Londoño, L. I., Torres-Soto, S., Naranjo-Tobón, V., Bedoya-Mejía, S., Madrigal-Cadavid, J., Chiquito-García, S., & Londoño-García, Á. (2026). Drug Survival of Biologic Therapy for Moderate‐to‐Severe Psoriasis in a Latin American Specialized Psoriasis Center: A 7‐Year Experience. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/1864210
Vancouver
Vallejo-Londoño LI, Torres-Soto S, Naranjo-Tobón V, Bedoya-Mejía S, Madrigal-Cadavid J, Chiquito-García S, et al. Drug Survival of Biologic Therapy for Moderate‐to‐Severe Psoriasis in a Latin American Specialized Psoriasis Center: A 7‐Year Experience. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/1864210
BibTeX
@article{VallejoLondoo2026,
author = {Vallejo-Londoño, Laura I. and Torres-Soto, Sneider and Naranjo-Tobón, Valentina and Bedoya-Mejía, Sebastián and Madrigal-Cadavid, Juliana and Chiquito-García, Susana and Londoño-García, Ángela},
title = {Drug Survival of Biologic Therapy for Moderate‐to‐Severe Psoriasis in a Latin American Specialized Psoriasis Center: A 7‐Year Experience},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/1864210}
}
EUVIMED